Investor Relations

Aduro is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.

NASDAQ ADRO (Common Stock)
March 20, 2019 4:00 p.m. ET

Stock Chart

Stock chart for: ADRO.O.  Currently trading at $3.91 with a 52 week high of $9.85 and a 52 week low of $2.34.

Data provided by Nasdaq. Minimum 15 minutes delayed.